Report copyright - The MUSCA Trial - GSK · The MUSCA Trial DREAM Phase II/III dose ranging efficacy and safety study Primary endpoint: Quality of Life, measured by SGRQ score ... MENSA Phase III exacerbation
Please pass captcha verification before submit form